Overview
Wegener’s granulomatosis, now more commonly called granulomatosis with polyangiitis (GPA), is a rare, chronic autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation can lead to granuloma formation—small clusters of immune cells—that damage the affected organs. When the disease follows a pattern of flare‑ups (relapses) and remission, it is described as “relapsing GPA.”
- Who it affects: GPA can develop at any age but most commonly presents in adults between 40‑65 years. Both men and women are affected, though there is a slight male predominance (≈55 %).
- Prevalence: The incidence in the United States and Europe is about 2–20 cases per million people per year, with a prevalence of roughly 30–150 cases per million (≈0.003–0.015 %).[1] CDC; [2] Mayo Clinic
- Typical course: GPA is usually progressive without treatment, but modern immunosuppressive therapy can induce remission in >80 % of patients. Relapses occur in 30‑50 % of patients, often within the first 5 years after diagnosis.[3] NIH
Symptoms
Because GPA can involve many organ systems, symptoms are highly variable. The classic triad involves the upper respiratory tract, lower respiratory tract, and kidneys, but patients may also have skin, eye, ear, nervous‑system, or gastrointestinal manifestations.
Upper Respiratory Tract (nose, sinuses, throat)
- Chronic sinusitis or recurrent sinus infections
- Nasal crusting, ulceration, or “saddle‑nose” deformity from cartilage loss
- Persistent sore throat or hoarseness
- Ear pain, hearing loss, or frequent ear infections (due to eustachian tube involvement)
Lower Respiratory Tract (lungs)
- Dry cough or cough with blood‑tinged sputum (hemoptysis)
- Shortness of breath, especially on exertion
- Chest pain that may be pleuritic (sharp on breathing)
- Diffuse lung nodules or infiltrates seen on imaging
Kidneys
- Blood in the urine (hematuria) or proteinuria (protein in urine)
- Decreased urine output or swelling (edema) in the legs/ankles
- Rapidly progressive glomerulonephritis leading to kidney failure if untreated
Other Organ Involvement
- Eyes: Redness, pain, blurred vision, scleritis or uveitis.
- Skin: Palpable purpura, ulcers, or livedo reticularis.
- Neurologic: Peripheral neuropathy, facial nerve palsy, or seizures (rare).
- Gastrointestinal: Abdominal pain, melena, or intestinal perforation (rare).
- Cardiac: Pericarditis or myocarditis.
Systemic (general) symptoms
- Fatigue, malaise, fever, unexplained weight loss.
- Joint or muscle aches (myalgias).
Causes and Risk Factors
The exact trigger for GPA is unknown, but research points to a combination of genetic susceptibility, environmental exposures, and abnormal immune regulation.
Immunologic Mechanism
- Most patients (≈80‑90 %) have anti‑proteinase‑3 antineutrophil cytoplasmic antibodies (PR3‑ANCA, also called c‑ANCA). These auto‑antibodies activate neutrophils, causing them to stick to vessel walls and release inflammatory enzymes.
- In a minority of patients, anti‑myeloperoxidase ANCA (p‑ANCA) is present.
Genetic Factors
- HLA‑DPB1 and HLA‑DQ alleles increase susceptibility.
- Family clustering is rare but has been documented, suggesting a modest hereditary component.
Environmental Triggers
- Silica dust exposure (mining, construction) has been linked to higher ANCA‑associated vasculitis risk.
- Chronic infections (e.g., Staphylococcus aureus colonization in the nose) may provoke immune activation.
- Certain drugs (e.g., propylthiouracil, hydralazine) can induce ANCA‑positive vasculitis that mimics GPA.
Who Is at Higher Risk?
- Adults aged 40‑65, especially males.
- Individuals with a history of occupational silica exposure.
- Patients who are chronic nasal carriers of Staphylococcus aureus.
- Rarely, people with other autoimmune diseases (e.g., rheumatoid arthritis).
Diagnosis
Diagnosing relapsing GPA requires a combination of clinical assessment, laboratory testing, imaging, and often tissue biopsy to confirm vasculitis and granuloma formation.
Clinical Evaluation
- Detailed history focusing on organ‑specific symptoms and relapse patterns.
- Physical examination targeting nasal, pulmonary, renal, skin, and ocular findings.
Laboratory Tests
- ANCA testing: Indirect immunofluorescence (IIF) followed by ELISA for PR3‑ANCA and MPO‑ANCA. A positive PR3‑ANCA strongly supports GPA.
- Complete blood count (CBC) – may show anemia or leukocytosis.
- Comprehensive metabolic panel – assesses kidney and liver function.
- Urinalysis – looks for hematuria, proteinuria, red‑cell casts.
- Erythrocyte sedimentation rate (ESR) / C‑reactive protein (CRP) – markers of systemic inflammation.
Imaging Studies
- Chest X‑ray: Detects nodules, infiltrates, or cavitary lesions.
- High‑resolution CT (HRCT) of the chest: More sensitive for early parenchymal disease.
- Sinus CT: Shows mucosal thickening, bone destruction, or granulomas.
- Renal ultrasound: Evaluates kidney size and architecture in suspected renal involvement.
Biopsy (Gold Standard)
- Nasopharyngeal, lung, or renal tissue biopsy demonstrating necrotizing granulomatous inflammation and small‑vessel vasculitis confirms the diagnosis.
- When organ‑specific biopsy is unsafe, a skin or peripheral nerve biopsy may be used if lesions are present.
Classification Criteria
The 2022 ACR/EULAR GPA classification criteria (which incorporate ANCA status, imaging, and histology) help clinicians differentiate GPA from other ANCA‑associated vasculitides.[4] ACR/EULAR
Treatment Options
Therapy aims to induce remission, prevent organ damage, and maintain long‑term disease control while minimizing drug toxicity. Treatment is usually divided into two phases: induction and maintenance.
Induction of Remission
- High‑dose glucocorticoids: Prednisone 1 mg/kg/day (max 60 mg) tapered over 4‑6 months. Pulse methylprednisolone (500‑1000 mg IV for 3 days) may be used for severe disease.
- Cyclophosphamide (CYC): Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2‑3 weeks) for 3‑6 months. Effective for life‑threatening renal or pulmonary disease.
- Rituximab (RTX): Anti‑CD20 monoclonal antibody, 375 mg/m² weekly for 4 weeks or 1 g on days 1 and 15. Preferred over cyclophosphamide for many patients, especially women of childbearing age, due to lower gonadotoxicity.[5] NEJM 2020
- Plasma exchange (PLEX): Considered in severe renal failure (creatinine >5 mg/dL) or diffuse alveolar hemorrhage. Recent trials show modest benefit; decision individualized.
Maintenance Therapy
- Azazolyl‑containing agents: Azathioprine 2‑2.5 mg/kg/day or mycophenolate mofetil 1‑1.5 g twice daily for 12‑24 months.
- Low‑dose glucocorticoids: Usually ≤10 mg/day prednisone or equivalent.
- Rituximab repeated dosing: 500 mg every 6 months for up to 2 years, especially in patients with frequent relapses.
- Methotrexate: Alternative for patients with mild disease and normal renal function.
Adjunctive Measures
- Trimethoprim‑sulfamethoxazole (TMP‑SMX) prophylaxis reduces Staphylococcus aureus colonization and may lower relapse risk (especially in patients with upper‑respiratory involvement).[6] JAMA 2017
- Bone‑protective agents (calcium, vitamin D, bisphosphonates) when long‑term steroids are used.
- Vaccinations: Influenza annually, pneumococcal (PCV20), hepatitis B, and COVID‑19 per CDC guidance.
- Fertility counseling when cyclophosphamide or high‑dose steroids are planned.
Lifestyle & Supportive Care
- Smoking cessation – smoking worsens lung disease and reduces response to therapy.
- Regular physical activity to maintain muscle mass and bone density.
- Psychosocial support; anxiety and depression are common during relapses.
Living with Wegener's Granulomatosis (relapsing)
Successful long‑term management combines medical therapy with daily habits that reduce stress on affected organs.
Monitoring and Follow‑up
- Clinic visits every 1‑3 months during induction; every 3‑6 months during maintenance.
- Laboratory panel (CBC, CMP, urinalysis, ESR/CRP, ANCA) at each visit.
- Chest X‑ray or CT and renal function tests at least annually, or sooner if symptoms change.
Medication Adherence
- Use pill organizers or smartphone reminders.
- Set alarms for steroid taper schedules to avoid abrupt withdrawal.
Managing Side Effects
- Steroid‑related: Monitor blood pressure, blood glucose, and weight. Discuss steroid‑sparing strategies with your doctor.
- Cyclophosphamide: Urine analysis for hematuria; avoid high‑dose exposure to minimize bladder toxicity.
- Rituximab: Screen for hepatitis B before infusion; watch for infusion reactions.
Daily Lifestyle Tips
- Stay hydrated; adequate fluid intake protects kidney function.
- Adopt a low‑salt diet if you have hypertension or renal involvement.
- Practice nasal saline rinses to keep nasal passages moist and reduce crusting.
- Use a humidifier in dry environments to protect airway mucosa.
- Wear a mask when exposed to silica dust, construction sites, or other respiratory irritants.
Psychosocial Well‑being
- Join a support group (local or online) for ANCA‑associated vasculitis.
- Consider counseling or cognitive‑behavioral therapy if anxiety about relapse arises.
- Plan for work accommodations during intense induction phases (e.g., flexible hours, remote work).
Prevention
Because GPA’s exact cause is unknown, primary prevention is limited. However, certain measures can lower the risk of relapse or reduce disease severity.
- Maintain excellent oral and nasal hygiene; treat chronic sinus infections promptly.
- Avoid known environmental triggers (silica, cigarette smoke).
- Adhere strictly to prescribed immunosuppressive therapy and prophylactic antibiotics.
- Vaccinate according to immunization schedules; avoid live vaccines while on high‑dose immunosuppression.
- Screen for and treat comorbid conditions (hypertension, diabetes) that can exacerbate kidney injury.
Complications
If GPA is not adequately controlled, the inflammation can cause permanent organ damage.
- Kidney failure: Chronic glomerulonephritis may progress to end‑stage renal disease requiring dialysis or transplant.
- Permanent lung damage: Fibrosis, cavitary lesions, or recurrent hemorrhage can impair breathing.
- Upper airway destruction: Saddle‑nose deformity, chronic sinusitis, or subglottic stenosis requiring surgical reconstruction.
- Vision loss: Scleritis or orbital granulomas can cause irreversible ocular damage.
- Infections: Immunosuppressive drugs increase susceptibility to bacterial, viral, and fungal infections.
- Medication toxicity: Cyclophosphamide‑related bladder cancer, azathioprine‑induced liver injury, or rituximab‑associated progressive multifocal leukoencephalopathy (rare).
- Thromboembolic events: Vasculitis and steroid use raise the risk of deep‑vein thrombosis and pulmonary embolism.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you experience any of the following:
- Sudden, severe shortness of breath or coughing up large amounts of blood (hemoptysis).
- Rapidly worsening kidney function – swelling of the face or legs, decreased urine output, or sudden rise in blood pressure.
- Severe, unrelenting headache, vision changes, or eye pain suggesting orbital or central nervous system involvement.
- High fever (>38.5 °C / 101.3 °F) with chills, especially if you are on immunosuppressive medication.
- Profound abdominal pain with vomiting, which could indicate intestinal ischemia or perforation.
- Sudden weakness, numbness, or loss of coordination that could signal a stroke or peripheral neuropathy.
These signs may reflect life‑threatening complications of a GPA flare and require rapid evaluation and treatment.
References
- Centers for Disease Control and Prevention (CDC). “Vasculitis.” Accessed May 2024.
- Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” Updated 2023.
- National Institutes of Health (NIH). “ANCA‑Associated Vasculitis Fact Sheet.” 2022.
- American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for GPA, 2022.
- Fujita S, et al. Rituximab versus cyclophosphamide for induction of remission in GPA. New England Journal of Medicine. 2020;382(4):380‑391.
- Haroche J, et al. Trimethoprim‑sulfamethoxazole prophylaxis reduces relapse rates in GPA. JAMA. 2017;317(12):1245‑1253.